Efficacy and safety of treatment with biologicals (benralizumab, dupilumab, mepolizumab, omalizumab and reslizumab) for severe eosinophilic asthma. A systematic …

I Agache, J Beltran, C Akdis, M Akdis… - Allergy, 2020 - Wiley Online Library
Five biologicals have been approved for severe eosinophilic asthma, a well‐recognized
phenotype. Systematic reviews (SR) evaluated the efficacy and safety of benralizumab,
dupilumab, mepolizumab, omalizumab and reslizumab (alphabetical order) compared to
standard of care for severe eosinophilic asthma. PubMed, Embase and Cochrane Library
were searched to identify RCTs and health economic evaluations, published in English.
Critical and important asthma‐related outcomes were evaluated for each of the biologicals …

Efficacy and safety of a bivalent RSV prefusion F vaccine in older adults

EE Walsh, G Pérez Marc, AM Zareba… - … England Journal of …, 2023 - Mass Medical Soc
Background Respiratory syncytial virus (RSV) infection causes considerable illness in older
adults. The efficacy and safety of an investigational bivalent RSV prefusion F protein–based
(RSVpreF) vaccine in this population are unknown. Methods In this ongoing, phase 3 trial,
we randomly assigned, in a 1: 1 ratio, adults (≥ 60 years of age) to receive a single
intramuscular injection of RSVpreF vaccine at a dose of 120 μg (RSV subgroups A and B, 60
μg each) or placebo. The two primary end points were vaccine efficacy against seasonal …